Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.
ISOLYTE M in Dextrose 5% is a crystalloid solution that provides water, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. The electrolytes (sodium, potassium, magnesium, chloride, acetate, and gluconate) maintain or restore intravascular volume and acid-base balance. Acetate and gluconate are bicarbonate precursors, metabolized in the liver and peripheral tissues to generate bicarbonate, thus correcting metabolic acidosis.
Fluid and electrolyte replacement,Maintenance of hydration and electrolyte balance in patients unable to tolerate oral intake,Correction of hypovolemia,Mild to moderate metabolic acidosis
FDA-approved: Maintenance and replacement of water, electrolytes, and calories in patients who cannot maintain adequate oral intake.,Off-label: Treatment of hypovolemia, correction of metabolic acidosis, and as a vehicle for intravenous drug delivery.
Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.
Intravenous infusion; dose determined by fluid and electrolyte requirements; typical adult rate 100-200 m L/hour.
Not applicable as a fixed drug. Electrolytes have no defined half-life; dextrose is rapidly cleared with a metabolic half-life of approximately 5-10 minutes due to insulin-mediated uptake.
No true terminal half-life; infused components (water and electrolytes) follow endogenous kinetics. Dextrose half-life approx. 1-2 hours, electrolytes distribute and are excreted based on renal function.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, primarily in the liver; insulin promotes cellular uptake. Electrolytes are not metabolized but are excreted or reabsorbed by the kidneys.
Dextrose undergoes glycolysis and the Krebs cycle to produce ATP, carbon dioxide, and water. Acetate is metabolized in the liver and peripheral tissues to form acetyl-Co A, which enters the Krebs cycle, generating bicarbonate. Gluconate is metabolized via the pentose phosphate pathway to produce ribulose-5-phosphate and eventually bicarbonate.
Electrolytes and dextrose are primarily excreted renally. Potassium, sodium, chloride, and magnesium are eliminated via kidneys. Dextrose is metabolized to CO2 and water, with negligible renal excretion. Biliary/fecal elimination is minimal (<5%).
Primarily renal; >90% of infused water and electrolytes are excreted unchanged via kidneys with minimal biliary or fecal elimination.
Negligible for electrolytes and dextrose (<5%).
Negligible for water and electrolytes; dextrose not bound. Total protein binding <5%.
Not applicable as a single compound. Electrolytes distribute primarily in extracellular fluid (0.2 L/kg for sodium), total body water (0.6 L/kg for water). Dextrose distributes in total body water (0.55 L/kg).
Sodium distributes primarily in extracellular fluid (Vd ~0.2 L/kg); water distributes in total body water (Vd ~0.6 L/kg). Dextrose distributes in extracellular and intracellular fluid with Vd ~0.2 L/kg initial.
Intravenous: 100%.
Intravenous: 100% bioavailability for all components; not administered by other routes.
No specific dose adjustment required; monitor serum electrolytes and fluid status in renal impairment due to risk of hyperkalemia, hypernatremia, or fluid overload.
Use with caution; monitor serum potassium and adjust infusion rate based on renal function; no specific GFR-based dose reduction defined.
No specific dose adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
No specific adjustment required; monitor electrolytes in severe hepatic impairment.
Weight-based: 2-6 m L/kg/hour or as per Holliday-Segar method for maintenance; monitor serum electrolytes closely.
Intravenous infusion; dose individualized based on weight and clinical status; typical rate 5-10 m L/kg/hour.
Use with caution; consider lower initial rates due to reduced renal function and increased risk of fluid overload; monitor electrolytes and volume status.
Use with caution due to possible renal impairment; monitor fluid and electrolyte status; adjust rate to avoid volume overload.
None for this product; however, caution is required in patients with congestive heart failure, renal impairment, or conditions predisposing to electrolyte imbalances.
None
Risk of fluid overload in patients with compromised cardiac or renal function,Risk of electrolyte imbalances (hyperkalemia, hyponatremia, hypernatremia),Administration may cause phlebitis or thrombosis,Monitor serum electrolytes, glucose, and fluid balance,Use with caution in patients with diabetes or glucose intolerance,Not for use when hyperosmolality is present
Use with caution in patients with renal impairment, heart failure, or conditions causing fluid overload.,Monitor serum electrolytes, blood glucose, and fluid balance.,Risk of hyperglycemia, hyperosmolarity, and dilutional hyponatremia.,Do not administer simultaneously with blood products through the same IV line due to risk of hemolysis.,Avoid rapid infusion to prevent metabolic acidosis from lactate accumulation (acetate may cause alkalosis if excessive).
Hyperkalemia,Severe renal impairment (oliguria or anuria),Severe metabolic alkalosis,Hypersensitivity to any component,Patients with known glucose-6-phosphate dehydrogenase deficiency (relative, due to potential for Heinz body formation)
Absolute: Hypersensitivity to any component, hypernatremia, hyperkalemia, hypermagnesemia, hyperchloremia, or severe metabolic alkalosis.,Relative: Severe renal impairment, oliguria, or conditions with risk of fluid overload (e.g., congestive heart failure, pulmonary edema).
No known food interactions. However, monitor dietary intake of sodium, potassium, and chloride to avoid electrolyte imbalances.
No specific food interactions. However, patients should maintain a balanced diet as per their medical condition. Avoid excessive intake of potassium-rich foods if at risk of hyperkalemia.
Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological constituents. However, maternal hyperglycemia from dextrose may increase fetal risks including macrosomia and congenital anomalies if glucose not controlled. First trimester: no direct teratogenicity, but dextrose-induced hyperglycemia may be associated with neural tube defects. Second/third trimester: risk of fetal hyperinsulinemia, macrosomia, neonatal hypoglycemia if maternal glucose elevated.
Isolyte M in Dextrose 5% is an intravenous electrolyte and caloric solution. At therapeutic doses, no teratogenic risk has been identified in animal studies; however, human data are limited. Inadvertent administration of large volumes leading to hyperglycemia or electrolyte imbalances (e.g., hyponatremia) could pose risks to the fetus. Use only when clearly needed and monitor maternal glucose and electrolytes closely.
Components are normal constituents of human milk. No specific M/P ratio data; dextrose, sodium, potassium, magnesium, chloride, acetate, gluconate are expected to transfer minimally. Use is compatible with breastfeeding. Monitor infant for electrolyte balance only if maternal levels are abnormal.
Dextrose and electrolytes are normal constituents of breast milk and are not expected to cause adverse effects in the breastfed infant at recommended doses. The M/P ratio is not applicable as components are endogenous. Use caution with high volumes or maternal glucose intolerance, but generally considered compatible with breastfeeding.
Pregnancy increases plasma volume and glomerular filtration rate; may require higher infusion rates to achieve desired electrolyte balance. Dextrose load may need adjustment to avoid maternal hyperglycemia, especially in gestational diabetes. No dose changes for electrolyte components themselves; monitor clinical response and serum levels.
Pregnancy may increase fluid requirements and alter electrolyte balance due to expanded plasma volume, increased glomerular filtration, and hormonal changes. No specific dose adjustments are established; doses should be individualized based on maternal clinical status, electrolyte levels, and glucose tolerance. Monitor for hyperglycemia due to decreased insulin sensitivity.
ISOLYTE H IN DEXTROSE 5% is a hypertonic solution (approximately 554 m Osm/L) that provides free water, electrolytes, and calories. Use caution in patients with renal impairment or those at risk for fluid overload. Monitor serum sodium, potassium, chloride, and glucose levels during infusion. Do not administer if solution is discolored or contains particulate matter. Compatible with most IV lines but avoid adding other drugs without checking compatibility.
Check serum potassium, magnesium, and phosphate levels before infusion; monitor serum glucose closely due to dextrose content. Adjust infusion rate based on volume status and renal function. Use with caution in patients with renal impairment or hyperkalemia. Ensure compatibility with co-administered IV medications.
This solution is given through a vein to provide fluids, electrolytes, and sugar.,Tell your healthcare provider if you have kidney problems, heart issues, or if you are on a low-sodium or low-potassium diet.,Report any signs of fluid overload such as swelling, shortness of breath, or rapid weight gain.,You may need blood tests to check your body's electrolyte levels and blood sugar.
This solution provides fluids, electrolytes, and calories to maintain hydration and electrolyte balance.,Report any signs of fluid overload (e.g., shortness of breath, swelling) or allergic reactions (e.g., rash, itching).,Inform your healthcare provider if you have kidney problems, diabetes, or are on a salt-restricted diet.,The infusion may cause changes in blood sugar levels; monitoring may be required if you have diabetes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.. ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by ISOLYTE M in Dextrose 5% is a crystalloid solution that provides water, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. The electrolytes (sodium, potassium, magnesium, chloride, acetate, and gluconate) maintain or restore intravascular volume and acid-base balance. Acetate and gluconate are bicarbonate precursors, metabolized in the liver and peripheral tissues to generate bicarbonate, thus correcting metabolic acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.. The standard adult dose of ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose determined by fluid and electrolyte requirements; typical adult rate 100-200 m L/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological const. ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Isolyte M in Dextrose 5% is an intravenous electrolyte and caloric solution. At therapeutic doses, no teratogenic risk has been identified in animal studies; however, human data ar. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.